Onctura has dosed the first subject in the Phase II OCULE-01 trial of oral roginolisib in individuals with metastatic uveal ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines.

Reports cash, cash equivalents and marketable securities as of December 31 were $36.1M compared with $85.7M as of December 31, 2023. These ...

Theratechnologies Inc.’s THTX share price has surged by 28.57%, which has investors questioning if this is right time to sell ...

BioAtla (NASDAQ:BCAB – Get Free Report) is anticipated to announce its quarterly earnings results after the market closes on ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery ...

Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a research report report ...

ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid ...

Ultraviolet (UV) radiation is known to cause DNA damage, and while that damage may accumulate and eventually lead to diseases ...